PDGFRA and pleomorphic liposarcoma: Studies in patient-derived orthotopic xenograft (PDX) models would provide further evidence in support of this idea; this approach has been used to show that PDGFRα-amplified pleomorphic liposarcoma is especially sensitive to pazopanib46.